Cargando…
Resistance to Rituximab Therapy and Local BAFF Overexpression in Sjögren’s Syndrome-Related Myoepithelial Sialadenitis and Low-Grade Parotid B-Cell Lymphoma
OBJECTIVE: B-cell expansion is a key feature of Sjögren’s syndrome (SS). Accordingly, several studies have reported the benefits of B-cell depletion with anti-CD20 monoclonal antibody (Rituximab) in the treatment of glandular and extraglandular manifestations of SS. Patients with SS are at increased...
Autores principales: | Quartuccio, Luca, Fabris, Martina, Moretti, Massimo, Barone, Francesca, Bombardieri, Michele, Rupolo, Maurizio, Lombardi, Sandra, Pitzalis, Costantino, Beltrami, Carlo Alberto, Curcio, Francesco, De Vita, Salvatore |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577948/ https://www.ncbi.nlm.nih.gov/pubmed/19088870 http://dx.doi.org/10.2174/1874312900802010038 |
Ejemplares similares
-
Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation
por: Quartuccio, Luca, et al.
Publicado: (2009) -
NKp30 Receptor Upregulation in Salivary Glands of Sjögren’s Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment
por: Pontarini, Elena, et al.
Publicado: (2021) -
Acute sialadenitis of parotid gland: Anaesthesia mumps
por: Kumar, Koramutla Pradeep, et al.
Publicado: (2014) -
High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients
por: Fabris, Martina, et al.
Publicado: (2022) -
Accumulation of Self-Reactive Naïve and Memory B Cell Reveals Sequential Defects in B Cell Tolerance Checkpoints in Sjögren’s Syndrome
por: Corsiero, Elisa, et al.
Publicado: (2014)